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Summary
Objective: Induction of growth-factor-based repair in full-thickness articular cartilage defects can be impaired by the upgrowth of blood
vessels and new bone into the cartilaginous compartment. We postulated that if an antiangiogenic factor (suramin) is included in the
chondrogenic matrix applied to the cartilaginous compartment of a full-thickness defect, vascular upgrowth and therefore bone formation will
be inhibited (functional barrier principle).
Design: Full-thickness defects were created in miniature pigs and the bony portion filled with a chondrogenic matrix. The cartilaginous
compartment was filled with the same matrix which additionally contained suramin, either in a free form or in free and liposome-encapsulated
forms. Animals were sacrificed 8 weeks after surgery and the extent to which bone tissue had encroached on the cartilaginous compartment
was graded semiquantitatively using light microscopy.
Results: In 63% of the control defects, bone represented more than 50% of the repair tissue present. In 10% of the defects treated with free
suramin, bone upgrowth was completely inhibited; in 55%, osseous tissue occupied 1–10% of the cartilaginous space and in the other 35%,
it represented 11–50% of the repair tissue present in this compartment. In 69% of the defects treated with free and liposome-encapsulated
suramin, bone upgrowth into the cartilaginous compartment was completely inhibited; in the remaining 31%, osseous tissue occupied no
more than 1–10% of this space.
Conclusions: To be effective, an antiangiogenic factor needs to be present at a sustained level throughout the chondrogenic treatment
course.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
Abbreviations: BMP-2, bone morphogenetic protein-2, IGF-1, insulin-like growth factor-1, TGF-β1, transforming growth factor-beta 1.
Introduction
A growth-factor-based approach to the induction of articular
cartilage repair has the advantage of avoiding cell or tissue
transplantation1. The availability of such strategies permits
the surgeon to act instantaneously on a decision to treat as
determined during exploratory surgery or arthroscopy2,3.
Using a small, partial-thickness articular cartilage defect
model, the biologic obstacles that must be overcome for
successful repair have been delineated1,4. Basically, the
lesion must be filled with a biodegradable matrix containing
a free chemotactic and mitogenic factor to stimulate the
migration of potential repair cells from the synovial pool
and their subsequent proliferation, and with a liposome-
encapsulated chondrogenic agent5 to induce a timely
transdifferentiation of primitive repair cells into chondro-
cytes, which then lay down cartilage.
Although this strategy works well for partial-thickness
defects, it cannot be applied to full-thickness lesions with-
out additional considerations being taken into account5.
This latter type of defect penetrates the subchondral bone
and bone-marrow spaces wherein reside an abundance of
different cell types6–8 (such as pericytes, perivascular
mesenchymal stem cells, hemopoietic cells, blood cells,
vascular endothelial cells and fat cells), some of which are
not only responsive to substances in the implanted
construct9–11, but respond in such a manner as to trigger
the onset of undesired angiogenic and osteogenic pro-
cesses. After stimulation by growth factors, blood vessels
grow rapidly from the bony floor of the defect and invade
the cartilaginous compartment so swiftly that the biologic
conditions soon become unfavorable to chondrogenesis
and conducive to osteogenesis12. By inserting a cell-
excluding membrane (or structural barrier13,14) at the
cartilage–bone interface, angiogenic activities and the de-
pendent osteogenic processes can be physically prevented
from encroaching on the cartilaginous compartment12.
However, optimal surgical placement of such a membrane
at the appropriate level cannot be readily achieved by
macroscopic inspection, nor is it easy to seal it completely
at the defect edges by press-fitting. Consequently, not only
does the cartilage–bone interface undulate in height, but
osseous tissue upgrowth occurs through microscopic
chinks between the membrane and defect walls. Moreover,
the long-term persistence of poorly biodegradable mem-
branes can prevent repair cartilage from becoming firmly
anchored to the underlying bone15,16, as can mild inflam-
matory responses triggered by slowly released degradation
products. The attachment of such ill-seated tissue is liable
to become additionally weakened with time owing to the
action of shear forces during normal joint usage17.
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An alternative therapeutic approach would be to apply a
functional barrier, such as an antiangiogenic substance,
which would chemically impede rather than physically block
vascular upgrowth into the cartilaginous compartment.
It was the aim of the current study to test the efficacy of
such a principle in achieving compartment-specific repair
tissue formation while avoiding the problems associated
with a structural barrier. The authors used a small, full-
thickness defect model in Goettingen miniature pigs12.
Lesions were filled with the same chondrogenic matrix that
was used to test the structural barrier principle12. However,
the construct implanted in the cartilaginous compartment
also contained the antiangiogenic factor suramin18,19. This
treatment strategy substantially impeded the upgrowth of
vessels and bone into the cartilaginous region, thereby
favoring a compartment-specific repair tissue result.
Materials and methods
SURGICAL PROCEDURE
Eight adult Goettingen miniature pigs (2–4 years of age)
were used for this study. General anesthesia was induced
by an intravenous injection of Narketan® (Chassot AG,
Belp, Switzerland) and maintained by administering
Halothan® (Halocarbon Laboratories, River Edge, NJ) and
nitrous oxide. The knee of each hind limb was exposed
and four full-thickness defects (approximately 0.8 mm in
depth×1.2 mm in width×7–8 mm in length) were created
through the articular cartilage layer of the trochlear groove
(two defects on the medial and two on the lateral facet)
using a custom-built planing instrument4. One (five
animals) or two (three animals) additional defects were
created in the medial femoral condyle of each knee. Eighty-
six defects were generated in the eight animals. These
were blotted dry and filled with an aqueous solution of
chondroitinase ABC (1 unit/ml [Sigma–Aldrich, Buchs,
Switzerland]), which was removed by swabbing after
4–5 min. Each defect was rinsed thoroughly with physio-
logic saline and again blotted dry12.
In six of the miniature pigs, defects received a matrix
composed of gelatin (Gelfoam®, Upjohn Company,
Michigan, MI) and fibrin (purified from bovine blood accord-
ing to the method described by Mosher and Blout20). In the
other two animals, defects received a matrix composed of
fibrin alone. The latter served as controls to exclude the
possibility of a gelatin-specific effect.
The matrix composed of fibrin alone was prepared as a
solution of fibrinogen (19 mg/ml of 0.15 mol Tris-buffered
saline [Merck, Dusseldorf, Germany]) to which human
thrombin (1 unit/ml [Immuno, Vienna, Austria]) was added
shortly before introduction into the defect. The matrix
composed of fibrin and gelatin was prepared as a solution
of fibrinogen (19 mg/ml) and gelatin (0.2 g/ml of 0.15 mol
Tris-buffered saline) to which human thrombin (1 unit/ml)
was added shortly before introduction into the defect.
Each matrix contained a free chemotactic and mitogenic
factor, either TGF-β1 (4 ng/ml, porcine platelet [R&D Sys-
tems Inc., Minneapolis, MN]) or IGF-1 (10 ng/ml, human
recombinant [Gibco Technologies, Basel, Switzerland]),
and a liposome-encapsulated differentiation agent, either
TGF-β1 (600 ng/ml) or BMP-2 (1 µg/ml [Genetics Institute,
Cambridge, MA]). Liposomes were prepared and drugs
incorporated according to the method described by Kim
et al.21.
The bony compartment of each defect was filled with one
of the matrix mixtures (Table I) and allowed to polymerize
in situ. The cartilaginous compartment of the same defect
was filled with the same matrix containing the same com-
bination of chemotactic factor and differentiation agent but
additionally containing the antiangiogenic drug suramin
(Germanin®, Bayer AG, Leverkusen, Germany [Fig. 1]).
Suramin was present either solely in a free form (0.4 mol/l)
or in free (0.4 mol/l) and liposome-encapsulated (0.4 mol/l)
forms (Table I). The 25 defects containing mixtures without
suramin (controls [Table I]) were distributed topographically
such that 10 were next to other suramin controls and 15
were next to suramin-containing lesions. These two sub-
groups were evaluated separately to determine whether
suramin had a local effect.
After in-situ polymerization of the matrix in the cartilagi-
nous compartment, wounds were closed layer by layer.
Postoperatively, the animals were permitted free cage
movement until sacrifice 8 weeks later. Miniature pigs were
sacrificed by administering a lethal dose of potassium
chloride (to induce cardiac arrest).
TISSUE PROCESSING AND ANALYSIS
Hind limbs were amputated and the knees freed of soft
tissues. The distal part of each femur was removed and
sawed into three pieces (the upper half of the trochlear
groove, the lower half of the trochlear groove, and the
medial femoral condyle) using a diamond band-saw (Exact
Medical Instruments, Oklahoma City, OK). For rapid histo-
logic examination, one 1.5-mm-thick slice was cut from the
lower half of the trochlear groove (parallel to the long axis),
cryofixed using carbon dioxide, cryosectioned (in the same
direction), and stained with toluidine blue O. The other
tissue pieces were fixed by immersion in 2.5% (volume per
volume) glutaraldehyde (Merck, Dusseldorf, Germany) and
2.5% (volume per volume) formaldehyde (Merck) buffered
(pH 7.4) with 0.1 mol sodium cacodylate (Merck) for 2–4
days at ambient temperature. They were then dehydrated
in ethanol and embedded in methylmethacrylate. Tissue
slices 1.2 mm thick were sawed perpendicular to the
longitudinal defect axis using a diamond saw (Leco,
Warrendale, PA), glued onto polished Plexiglas object
holders (Altumax France SA, Paris La De´fense, France),
milled to a thickness of approximately 100–150 µm with a
Polycut E (Reichert-Jung, Heidelberg, Germany), polished,
surface-stained with McNeil’s tetrachrome, toluidine blue
O, and basic fuchsin1, and examined in a Vanox AH-2 light
microscope (Olympus, Tokyo, Japan). Five to six tissue
slices were produced along the length of each defect, three
of these being randomly selected for semiquantitative
histologic analysis (Table I).
Repair tissue laid down in the cartilaginous compartment
of each defect was assessed qualitatively for its resem-
blance to native cartilage, with cell morphologic features
and staining characteristics of the intercellular matrix being
used as the relevant criteria. The percentage transfor-
mation of primitive mesenchymal repair tissue into cartilage-
like tissue was estimated by point counting using a stand-
ard grid system22. In the bony compartment, osseous
tissue was identified on the basis of its morphologic fea-
tures and staining characteristics. The proportion of tissue
represented by bone in the cartilaginous compartment
was assessed semiquantitatively as falling into one of four
categories: no bone formed (0%); 1–10% of the compart-
ment’s volume occupied by bone; 11–50% of the compart-
ment’s volume occupied by bone; and greater than 50% of
the compartment’s volume occupied by bone (Table I).
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Table I
Treatment strategies and histologic findings
Composition of the chondrogenic matrix applied to the bony and cartilaginous
compartments of each defect
Form of suramin in matrix
applied to cartilaginous
compartment
Total number
of defects per
experiment
Number and percentage (in parentheses) of
sections with the indicated proportions of bone
tissue in the cartilaginous compartment
Matrix Chemotactic and mitogenic factor
(free form)
Differentiation factor
(liposome-encapsulated)
0% 1–10% 11–50% >50%
Gelatin and fibrin TGF-β1 TGF-β1 No suramin 10 0 (0%) 0 (0%) 12 (40%) 18 (60%)
Gelatin and fibrin IGF-1 BMP-2 No suramin 15 0 (0%) 0 (0%) 15 (33%) 30 (67%)
Gelatin and fibrin TGF-β1 TGF-β1 Free 10 6 (20%) 15 (50%) 9 (30%) 0 (0%)
Gelatin and fibrin IGF-1 BMP-2 Free 10 0 (0%) 18 (60%) 12 (40%) 0 (0%)
Gelatin and fibrin TGF-β1 TGF-β1 Free and liposome-encapsulated 26 57 (73%) 21 (27%) 0 (0%) 0 (0%)
Gelatin and fibrin IGF-1 BMP-2 Free and liposome-encapsulated 15 51 (65%) 27 (35%) 0 (0%) 0 (0%)
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Results
Semiquantitative data pertaining to the experimental
findings are summarized in Table I and graphically shown in
Fig. 2. In control defects which had received no suramin
and in which no antiangiogenic effect had been exerted,
there was upgrowth of osseous tissue into the cartilaginous
compartment in all cases. The degree of bone upgrowth
into the cartilaginous compartment varied greatly, not only
between different defects (Fig. 3) but also along the length
of any particular lesion. Generally, however, the proportion
of the repair tissue represented by bone within the cartilagi-
nous compartment exceeded 50% (Fig. 2). No significant
difference in this parameter was observed between control
defects whose neighbors in the same joint were controls
(n10) and those which were neighbored by suramin-
treated defects (n15). This finding indicates that suramin
had not leaked out of the defect to a significant degree. The
distribution profile of numerical data was not influenced by
the nature of the growth factor system used (free TGF-β1
and liposome-encapsulated TGF-β1 or free IGF-1 and
liposome-encapsulated BMP-2).
In defects that had been treated with suramin in a free
form alone (Fig. 4), upgrowth of osseous tissue into the
cartilaginous compartment was only partially inhibited. As
with controls, the degree of encroachment was variable;
nevertheless, an obvious shift toward the lower-percentile
categories was apparent, with a slight skew in favor of the
1–10% category being observed (Table I; Fig. 2). No more
than 50% of the tissue laid down in the cartilaginous
compartment of the defects was bone. The distribution
profile of numerical data was not influenced by the nature of
the growth factor system used. Most of the bone present
was woven, which had been formed by direct ossification,
not via the enchondral route.
In defects that had been treated with liposome-
encapsulated and free suramin (Fig. 5), a dramatic sup-
pression of osseous tissue upgrowth into the cartilaginous
compartment was observed. In the majority of cases (69%),
virtually no bone was present, and in no instance did it
represent more than 10% of the total tissue volume
(Table I; Fig. 2). The distribution profile of numerical data
was not influenced by the nature of the growth factor
system used.
The osseous compartment of each defect void was filled
completely with highly vascularized woven bone (Figs.
3–5), bone marrow and adipose tissue. The mechanism of
ossification could not be ascertained at the time of analysis
(8 weeks postoperatively), bone formation being complete
at this stage and remodeling activities well underway in
some locations. Along the defect margins, repair and native
tissue were well knit. That no differences between groups
were observed in the bony compartment of defects
indicates that suramin did not seep downward from the
cartilaginous compartment to an appreciable degree.
The interface between repair cartilage and repair bone
tissues generated in their respective compartments contin-
ued at the same level as that in the native surroundings,
local deviations being no more than ±20%. These undu-
lations were thought to reflect corresponding irregularities
in the surface contour of the matrix introduced into the bony
compartment during surgery. The two types of repair tissue
were generally well knit in the plane of juxtaposition, which
implies that suramin did not interfere with the integration
process. The cartilage-like quality of tissue laid down in the
cartilaginous compartment was similar using each of the
two growth factor systems. The degree of transformation
from mesenchymal tissue to cartilage-like tissue was in the
range 50–80%, which corresponds to that found in a
previous study1. This finding indicates that suramin
had no influence on either the migration of cells from the
synovium, their proliferation, or their differentiation into
chondrocytes.
Fig. 1. The set-up used to test the functional barrier principle is shown. First the bony and then the cartilaginous compartment of a shallow,
full-thickness defect were filled with a chondrogenic matrix. In the latter instance, the matrix contained the antiangiogenic factor suramin,
whereas in the former, no such substance was included.
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Residues of gelatin were sometimes observed in the
cartilaginous compartment of defects that had been treated
with the composite matrix, whereas fibrin was always
completely resorbed, irrespective of whether it had formed
a part or the whole of an implant. Since gelatin is known
to degrade less rapidly than fibrin, this finding is not
suggestive of a suramin-related effect. In the bony compart-
ment, no traces of gelatin were ever observed in any of the
defects, indicating that its remodeling was more efficient in
this well-vascularized region.
Discussion
The functional barrier principle (Fig. 1) arose from the
need to inhibit vascular invasion of, and bone formation in,
the cartilaginous compartment of full-thickness defects12.
The success of this concept hinges on the premis that in
the absence of blood vessels, osteogenesis cannot take
place23–26. The angiogenic drug suramin18,19,27 was
chosen as the functional barrier compound.
The surgical procedure posed no difficulties. A composite
matrix of gelatin and fibrin was selected for its good volume
stability. Purely fibrinous implants are known to shrink
uncontrollably during polymerization in situ1, which can
lead to poor integration between repair and native tissue
along the defect floor and walls and to a concave articular
surface. The non-suramin-containing matrix placed in the
bony compartment could be leveled accurately by macro-
scopic inspection at the prospective cartilage–bone inter-
face. The microscopic findings confirmed that the
regenerated height of this junction corresponded to its level
in the native surroundings. Local fluctuations did not ex-
ceed ±20% of the articular cartilage height (approximately
700 µm), which is within the limits of acceptability. It was
considered best to slightly underfill the bony portion of the
defect with the matrix lacking suramin and to overfill, to a
corresponding degree in a downward direction, the carti-
laginous compartment with the suramin-containing matrix
[Fig. 5(C)]. Under these conditions, repair tissue laid down
in each compartment will be remodeled and the natural
level of the cartilage–bone interface eventually reestab-
lished6,7,28. In the event of the osseous defect space being
overfilled [Fig. 5(D)], it is unlikely that the bone tissue laid
down above the natural border will be replaced by cartilage,
because once vessels have invaded the cartilaginous
region, the process cannot be reversed by any known
physiologic or pathologic mechanism.
Eight weeks after surgery, osseous defect spaces were
filled with well-vascularized woven bone, bone marrow and
adipose tissue (Figs. 3–5), irrespective of the growth factor
system used, indicating that osteogenesis had been stimu-
lated efficiently. In some locations, remodeling into lamellar
bone was already underway [Fig. 3(A)]. Repair and native
bone tissue were well integrated along the lesion borders.
Suramin was only partially effective in suppressing bone
tissue upgrowth into the cartilaginous defect space when
present in a free form alone (Fig. 4), but highly efficacious
when included in a delayed-release system (liposomes). In
the latter case (Fig. 5), the cartilaginous compartment of
most defects (69%) contained no bone, whereas in the
remainder, it constituted maximally 10% of the repair tissue
volume. These findings suggest that the half-life of freely
dissolved suramin is short and that to be fully efficacious
this compound must be present throughout the healing
period.
Tissue transformation into cartilage within the cartilagi-
nous compartment was approximately 50–80%, which
corresponds to the range previously found using a partial-
thickness defect model1. This finding shows that, at the
concentration used, suramin neither inhibited the migration
of cells from the synovium nor influenced their metabolic
(remodeling) activity or capacity to differentiate into
chondrocytes. Given the small volume of matrix deposited
in the defects of each joint, and therefore the low total dose
of suramin applied, no systemic effects were to be ex-
pected. In clinical practice, this compound is administered
systemically at much higher levels in the treatment of
sleeping sickness and onchocerciasis29–31.
Fig. 2. (A) Semiquantitative histologic findings relating to control
defects. In the absence of suramin, bone upgrowth into the
cartilaginous compartment occurred in all defects; and in most
instances (63%), osseous tissue represented more than 50% of
the repair tissue present. (B) Semiquantitative histologic findings
relating to defects whose cartilaginous compartment was treated
with free suramin. In this group of defects, bone never represented
more than 50% of the repair tissue present in the cartilaginous
compartment; and in 65%, it was either absent altogether (10%) or
occupied no more than 1–10% of this space (55%). (C) Semi-
quantitative histologic findings relating to defects whose cartilagi-
nous compartment was treated with free and liposome-
encapsulated suramin. In this group of defects, osseous tissue
never occupied more than 10% of the repair tissue present in
the cartilaginous compartment; and in 69%, bone upgrowth was
completely inhibited.
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The current study shows that the functional barrier prin-
ciple can be implemented with good effect in the
growth-factor-based treatment of full-thickness defects. Its
advantages over the structural barrier principle are that it
triggers no inflammatory response at the interface between
cartilaginous and bony compartments and that it permits
better integration between repair tissue types at this junc-
tion. As a result, repair tissue would be expected to have
greater mechanical competence. However, this concept
has been tested only in a small, full-thickness defect model.
Fig. 3. (A) Light micrograph of a shallow, full-thickness defect 8 weeks after treating the entire lesion void with a chondrogenic matrix that
contained no suramin. Osseous tissue (O) has grown upward from the subchondral bone region (S) and completely fills the bony
compartment, of the defect. In the absence of an antiangiogenic factor (suramin), osseous tissue has grown unimpeded into the cartilaginous
compartment where it constitutes approximately two-fifths of the repair tissue present. The remainder of the cartilaginous compartment
contains a mixture of primitive mesenchymal and cartilage-like repair tissue (R). The partially differentiated cartilage-like tissue can be
distinguished from native hyaline cartilage (N) by its higher numerical density of cells and coarser fibrillar nature. The newly formed osseous
tissue has been remodeled into lamellar bone at most locations. An 80-µm-thick section, surface-stained with McNeil’s tetrachrome, toluidine
blue O, and basic fuchsin. Bar=150 µm. (B) Light micrograph of a shallow, full-thickness defect 8 weeks after receiving the treatment
described in (A). In this example, osseous tissue (O) occupies approximately one-half of the repair tissue laid down in the cartilaginous
compartment. In contrast to (A), the newly formed osseous tissue has not yet been remodeled into lamellar bone but still has the morphologic
features and staining characteristics of the woven type. S, subchondral bone; R, primitive mesenchymal and cartilage-like repair tissue; N,
native hyaline cartilage. An 80-µm-thick section, surface-stained with McNeil’s tetrachrome, toluidine blue O, and basic fuchsin. Bar=150 µm.
Fig. 4. (A) Light micrograph of a shallow, full-thickness defect 8 weeks after treatment of the bony portion with a chondrogenic matrix lacking
suramin and of the cartilaginous compartment with the same chondrogenic matrix containing free suramin. Despite the presence of free
suramin, the osteogenic repair response (O) emanating from the subchondral bone bed (S) still encroached on the cartilaginous defect
space, although to a lesser degree than when no antiangiogenic factor was included in the chondrogenic matrix (as shown in Fig. 3). The
remainder of the cartilaginous compartment is occupied by a mixture of primitive mesenchymal and cartilage-like repair tissue (R), which is
readily distinguishable from native hyaline cartilage (N). An 80-µm-thick section, surface-stained with McNeil’s tetrachrome, toluidine blue O,
and basic fuchsin. Bar=150 µm. (B) Light micrograph of a shallow, full-thickness defect 8 weeks after receiving the treatment described in
(A). In this example, osseous tissue (O) occupies a larger proportion of the cartilaginous compartment than is the case in (A). The remainder
of this compartment contains a mixture of primitive mesenchymal and cartilage-like repair tissue (R), similar in composition to that present
in (A). S, subchondral bone; N, native hyaline cartilage. An 80-µm-thick section, surface-stained with McNeil’s tetrachrome, toluidine blue O,
and basic fuchsin. Bar=200 µm.
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Additional studies are needed to adapt this concept to
larger lesions.
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